pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

theraclone-sciences PRESS RELEASE ARCHIVE

Apr 30, 2015

Theraclone Sciences' I-STAR™ Technology Chosen by Wellcome Trust to Identify Therapeutic Antibodies Against Ebola Virus

Apr 24, 2014

Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies Discovered with Theraclone Technology

Dec 2, 2013

PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences

Nov 4, 2013

Theraclone Sciences’ Monoclonal Antibody Candidate PGT121 Suppresses HIV in Simian Models of Disease

Sep 11, 2013

Theraclone Sciences Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013

Sep 10, 2013

Theraclone Sciences Announces Initiation of Phase 2a Trial of TCN-202 for the Prevention of Human Cytomegalovirus Infection

Sep 8, 2013

Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study

Aug 1, 2013

PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets

Apr 2, 2013

Theraclone Sciences Announces Positive Top-line Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection

Mar 25, 2013

Theraclone Sciences Secures $14 Million in Additional Financing

Oct 25, 2012

Theraclone Sciences Initiates Phase 2 Viral Challenge Clinical Study of Therapeutic Antibody for the Treatment of Influenza A

Sep 10, 2012

Theraclone Sciences Presents Phase 1 Results of TCN-032, its Therapeutic Antibody Directed at Influenza A, at ICAAC 2012

Jun 14, 2012

Theraclone Sciences Announces Initiation of a Phase 1 Clinical Trial of TCN-202, an Antibody in Development for the Treatment of Human Cytomegalovirus Infection

May 15, 2012

Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of its Therapeutic Antibody Directed at Influenza A

Dec 6, 2011

Theraclone Sciences Announces Appointment of Clifford Stocks as CEO

Sep 21, 2011

Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A

Sep 8, 2011

Theraclone Sciences Secures $10.6 Million in Series B Extension Financing

Sep 6, 2011

Theraclone Sciences Named a 2011 Fierce 15 Biotech by FierceBiotech

Google Analytics Alternative